Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
Authors' conclusion
LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels
Study context
- Population
- Adults with mixed hyperlipidemia36 men · 12 women
- Participants
- 48 adults
- Comparison
- LY3475766 vs placebo
- Outcome
- Safety
Methodological detailsascending doses
- Ascending doses
Main finding
As reported in the abstract
- Well tolerated; no severe AEs or AE-related discontinuations
- 0
Secondary outcomes
Lipids (pharmacodynamics), vs placebo
- Triglycerides
- −70%
- Remnant cholesterol
- −86%
- LDL-C
- −32%
- Non-HDL-C
- −35%
- Apolipoprotein B
- −29%
- HDL-C
- +27%
- Dose-dependent reductions
Safety
- No severe AEs or AE-related discontinuations with LY3475766
Original publication
Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. Nat Med. Published 10 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →